PT Indofarma Tbk (INAF) targets profit growth for the current year this year of around 4,677% to Rp140.35 billion compared to the previous year's realization of only Rp30 million.

Based on Indofarma's annual report for the 2020 financial year, this projection is supported by a plan to achieve revenue of around Rp2.54 trillion or a growth of 48.42% from the previous year's realization of Rp1.71 trillion.

The company estimates the cost of goods sold to increase by 44.84% from Rp1.31 trillion to Rp1.90 trillion, in line with the increase in revenue.

The pharmaceutical company projects the tax burden to swell by around 159.17% to Rp46.78 billion by the end of this year from the previous year's achievement of only Rp18.05 billion.

Indofarma projects total assets to increase by 17.69% to Rp2.01 trillion from Rp1.71 trillion.

The company targets cash and cash equivalents by the end of this year to be at the level of Rp378.74